SPEXIS Archives | SPRIM Global Investments

Spexis Announces Usd $2.5 Million Capital Commitment To Support The Upcoming Phase 3 Colifin® Studies

BIOTECH

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

August 14, 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases...

Spexis Announces Closing Of Capital Commitment Of Usd 4.5 Million From Sprim Global Investments (sgi) To Enable Initiation Of Colifin® Phase 3 Study

BIOTECH

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today...

Spexis And Sprim Global Investments (sgi) Announce Plans For Clinical Trial Partnership To Fund Up To Half Of The Projected Phase 3 Clinical Development Costs Of Colifin®

BIOTECH

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

February 8, 2023

Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up...

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.